Publicaciones (23) Publicaciones de SEVERINA DOMÍNGUEZ FERNÁNDEZ

2022

  1. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study

    Frontiers in Pharmacology, Vol. 13

  2. Urgent and unexpected findings in oncology and hematology patients: a practical approach to imaging

    Radiologia, Vol. 64, Núm. 5, pp. 464-472

2021

  1. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies

    Annals of Medicine, Vol. 53, Núm. 1, pp. 762-769

2019

  1. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  2. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin

    Frontiers in Oncology, Vol. 9, Núm. MAR

2018

  1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

  2. Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: Pooled analysis in 4 basque country university hospitals

    ClinicoEconomics and Outcomes Research, Vol. 10, pp. 189-199

2017

  1. Valoración del coste económico del cáncer colorrectal según estadio tumoral

    Cirugia Espanola, Vol. 95, Núm. 2, pp. 89-96

2016

  1. Growing teratoma syndrome: An unusual evolution of treated ovarian immature teratoma - A case report

    European Journal of Gynaecological Oncology, Vol. 37, Núm. 5, pp. 729-731

2010

  1. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

    Breast Cancer Research and Treatment, Vol. 123, Núm. 1, pp. 149-157

2004

  1. Anti-emetic efficacy of oral granisetron in the total control of late-onset emesis induced by cyclophosphamide-containing chemotherapy

    Revista de oncología: Publicación oficial de la Federación de Sociedades Españolas de Oncología y del Instituto Nacional de Cancerología de México, Vol. 6, Núm. 1, pp. 22-29

  2. Anti-emetic efficacy of oral granisetron in the total control of late-onset emesis induced by cyclophosphamide-containing chemotherapy

    Clinical and Translational Oncology, Vol. 6, Núm. 1, pp. 22-29

2003

  1. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

    Annals of Oncology, Vol. 14, Núm. 6, pp. 867-872

  2. Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer

    Lung Cancer, Vol. 39, Núm. 1, pp. 77-84

2002

  1. Predictive value of P53, BCL-2, and BAX in advanced head and neck carcinoma

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 25, Núm. 6, pp. 588-590

1998

  1. Informacion en oncologia: Evaluacion de un modelo basado en la autonomia del paciente

    Oncologia, Vol. 21, Núm. 12, pp. 33-38

1995

  1. Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: A preliminary report

    International Journal of Radiation Oncology, Biology, Physics, Vol. 33, Núm. 3, pp. 675-682

1994

  1. Aztreonam in association with piperacillin as an empirical antibiotic treatment in febrile granulocytopenic patients with solid tumors

    Oncology Reports, Vol. 1, Núm. 1, pp. 233-236

1993

  1. Ifosfamide in advanced epidermoid head and neck cancer

    Cancer Chemotherapy and Pharmacology, Vol. 31, Núm. 4, pp. 340-342